In order to realize the ambition of RegMed XB to bring solutions to the patients on a large scale the RM products we develop will have to be commercialized. This will ensure large-scale production and efficient production methods to reduce costs. Furthermore, the expertise in the RegMed XB ecosystem can also boost the development of new and existing products from the emerging RM companies. All in all, it is a perfect match to partner up with companies to access their expertise to design scalable and feasible products and together scout for opportunities to valorize new opportunities in the pipeline of the companies or the academic partners. Currently, we have strong partnerships with the following entities.
Access2Bone is a start-up in the orthopaedic market of bone void fillers. Worldwide the number of bone grafting procedures performed in an ever more geriatric population is growing rapidly. For a growing group of geriatric patients with a compromised bone regeneration metabolism Access2Bone is to create the best bone void filling solutions surgeons need to help these patients best. Access2Bone envisions to lead the high-end segment of bone void fillers by creating highly osteo inductive products that are safe by design and disruptively efficient. Access2Bone’s products are based on naturally derived growth factors. Access2Bone is aiding the Osteoarthritis Moonshot with coating implants that being developed by the Moonshot team with A2B’s growth factors to stimulate fusion between the patient’s bone and the implants being developed.
Biomotion Technologies has stepped forward to participate in the new projects RegMed XB is preparing. We are very excited by this and look forward to formalizing their participation." Biomotion produces multi-technology 3D bioprinting systems. The closed-loop architecture of these systems ensures the consistent fabrication of biological constructs. The open hardware approach further enables modifications by the users, including novel printheads and printing surfaces. Biomotion Technologies - Automation & Reliability in 3D Bioprinting.
Osteo--Pharma is a Life Sciences company that focuses on bone regeneration and is developing innovative medical devices and pharmaceuticals for the orthopedic and dental field. Osteo-Pharma applies its patented, OsteoActivator® technology that enables sustained delivery over multiple weeks of ancillary amounts of bone healing compounds for local treatment of a bone fracture or bone defect. The European Patent Office has recently granted a composition of matter patent covering OsteoActivator® formulations. The Osteo-Pharma portfolio consists of:
- OsteoActivator coated collagen membranes with enhanced “guided bone regeneration” characteristics
- Spray coated implants e.g. for orthopedic and dental screws
- Osteo-Activator microspheres as an injectable formulation designed for intra-osseous bone treatments such as bone marrow lesions (BML) in subchondral bone of osteoarthritis patients or spinal compression fractures by direct injection into the vertebra.
Osteo-pharma has successfully completed pre-clinal studies and is now actively advancing its lead products towards the clinic and market.
Scinus Cell Expansion Netherlands
Scinus Cell Expansion develops and distributes bioreactor technology for stem cell cultivation. The system enables clinical scale cell cultivation in a controlled environment, which we feel is a cost effective alternative to 2D cell growth in tissue culture flasks or cell stacks. The system contains a single use bioreactor bag that can be used to cultivate stem cells (e.g. human mesenchymal stromal cells) to clinically relevant numbers of cells. Adherent cells are grown on microcarriers in a single use, expandable bioreactor bag with continuous pH and dissolved oxygen control and biomass monitoring, which provides an optimized environment for growing cells. In addition to that, Scinus is also working on expansion of suspension cells (like T-Cells, NK Cells). Therefore we have a dedicated single use suspension bioreactor bag. The closed system minimizes the risk of contamination. For an illustrative animation, please check our website.
A clinical-stage medical device company, Xeltis developed the world’s first polymer-based technology platform to enable natural restoration of heart valves and blood vessels within the body.
The technology uses the patient’s own natural healing system to develop a new living functional vascular graft or heart valve. Xeltis devices are made of supramolecular polymers (a Nobel prize awarded discovery). They are manufactured with electrospinning methods to create small diameter vascular grafts and heart valve implants with a unique micro-porous architecture.
Quality Assistance is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.
The company holds a unique place on the market with all of its laboratories on one site, 230 highly-qualified professionals and 40 years’ expertise at the forefront of analytical sciences.
They assist their clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using their state-of-the-art, product-dedicated expertise in analytical sciences. For each customer and each project, they design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.